ESMO Congress 2021 Conference Review - focus on Renal Cancer

In this review:

Belzutifan + cabozantinib for advanced clear-cell RCC
Frontline cabozantinib in metastatic collecting duct RCC
Nivolumab outcomes in metastatic RCC according to antibiotic exposure
Withholding or continuing sunitinib or pazopanib in locally advanced/metastatic renal cancer
Nivolumab + alternatively scheduled ipilimumab in advanced RCC
Adjuvant pembrolizumab in RCC
Conditional survival and 5-year follow-up in CheckMate 214
Avelumab + axitinib vs. sunitinib outcomes in metastatic RCC according to nephrectomy status
Nivolumab + cabozantinib vs. sunitinib outcomes in advanced RCC according to nephrectomy status
First-line pembrolizumab in advanced non-clear-cell RCC:≥34-month results

Please login below to download this issue (PDF)

Subscribe